Ovarian hyperstimulation syndrome: Reviewand new classification criteria for reporting in clinical trials

Human Reproduction

Volumn 31, Issue 9, 2016, Pages 1997-2004

  Humaidan, P ^a   Nelson, S M ^b   Devroey, P ^c   Coddington, C C ^d   Schwartz, L B ^e   Gordon, K ^e   Frattarelli, J L ^f   Tarlatzis, B C ^g   Fatemi, H M ^h   Lutjen, P ⁱ   Stegmann, B J ^e  

^a SKIVE REGIONAL HOSPITAL   (Denmark)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^d MAYO CLINIC   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f Hawaii Institute of Geophysics   (United States)

^g PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^h IVI GCC Fertility   (United Arab Emirates)

ⁱ MONASH IVF   (Australia)

Author keywords

Assisted reproductive technology; Classification criteria; Clinical trials; In vitro fertilization; OHSS flow diagram; Ovarian hyperstimulation syndrome; Ovarian stimulation

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; KISSPEPTIN;

ABDOMINAL DISCOMFORT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONSENSUS; CRYOPRESERVATION; DIARRHEA; DISEASE CLASSIFICATION; EMBRYO SEGMENTATION; FEMALE; HUMAN; NAUSEA; OOCYTE MATURATION; OVARY HYPERSTIMULATION; PATHOPHYSIOLOGY; PREGNANCY TEST; REVIEW; RISK FACTOR; STOMACH DISTENSION; VOMITING; CLASSIFICATION; IN VITRO FERTILIZATION; INCIDENCE; INTRACYTOPLASMIC SPERM INJECTION; OVULATION INDUCTION; PROCEDURES;

CLINICAL TRIALS AS TOPIC; FEMALE; FERTILIZATION IN VITRO; HUMANS; INCIDENCE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 84988979514     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dew149     Document Type: Review

References (54)

1. Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Nijher GM, Comninos AN, Peters D, Buckley A, Ratnasabapathy R et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. J Clin Endocrinol Metab 2015; 100: 3322-3331.
2. Aboulghar M, Evers JH, All-Inany H. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: A Cochrane review. Hum Reprod 2002; 17: 3027-3032.
3. Abramov Y, Elchalal U, Schenker JG. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: A multicenter study. Fertil Steril 1999; 71: 645-651.
4. Alvarez C, Marti-Bonmati L, Novella-Maestre E, Sanz R, Gomez R, Fernandez-Sanchez M, Simon C, Pellicer A. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007; 92: 2931-2937.
5. Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: Definition of high risk groups. Hum Reprod 1991; 6: 1395-1399.
6. Bellver J, Munoz EA, Ballesteros A, Soares SR, Bosch E, Simon C, Pellicer A, Remohi J. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: A randomized controlled study. Hum Reprod 2003; 18: 2283-2288.
7. Braat DDM, Schutte JM, Bernardus RE, Mooij TM, van Leeuwen FE. Maternal death related to IVF in the Netherlands 1984-2008. Hum Reprod 2010; 25: 1782-1786.
8. Brinsden PR,Wada I, Tan SL, Balen A, Jacobs HS. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995; 102: 767-772.
9. Chen CD, Wu MY, Chen HF, Chen SU, Ho HN, Yang YS. Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndrome. Human Reproduction 2000; 15: 66-71.
10. Cluroe AD, Synek BJ.Afatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology 1995; 27: 344-346.
11. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum Reprod Update 2002; 8: 559-577.
12. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 2003; 9: 77-96.
13. Delvigne A, Kostyla K, Murillo D, Van Hoeck J, Rozenberg S. Oocyte quality and IVF outcome after coasting to prevent ovarian hyperstimulation syndrome. Int J Fertil Womens Med 2003; 48: 25-31.
14. Devroey P, PolyzosNP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 2011; 26: 2593-2597.
15. Enskog A, Henriksson M, Unander M, Nilsson L, Brannstrom M. Prospective study of the clinical and laboratory parameters of patients inwhomovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999; 71: 808-814.
16. Fabregues F, Balasch J, Manau D, JimenezW, Arroyo V, Creus M, Vanrell JA. Hematocrit, leukocyte and platelet counts and the severity of the ovarian hyperstimulation syndrome. Hum Reprod 1998; 13: 2406-2410.
17. Fatemi HM, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, Garcia-Velasco JA. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-All" approach in GnRH antagonist protocol. Fertil Steril 2014; 101: 1008-1011.
18. Gaafar SS, El-Gezary DA, El Maghraby HA. Early onset of cabergoline therapy for prophylaxis against ovarian hyperstimulation syndrome; a potentially safer and more effective protocol. Fertil Steril 2014; 102: E308.
19. Garcia-Velasco JA, Pellicer A. New concepts in the understanding of the ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol 2003; 15: 251-256.
20. Geva E, Jaffe RE. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 2000; 74: 429-438.
21. Gokmen O, Ugur M, Ekin M, Keles G, Turan C, Oral H. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: A prospective randomized placebo controlled study. Eur J Obstet Gynecol Reprod Biol 2001; 96: 187-192.
22. Golan A. A modern classification of OHSS. Reprod Biomed Online 2009; 19: 28-32.
23. Golan A, Ron-el R, Herman A, Soffer Y,Weinraub A, Caspi E. 1989 Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Surv 1989; 44: 430-440.
24. Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH. Increased capillary permeability induced by human follicular fluid: A hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 1995; 63: 268-272.
25. Graf MA, Fischer R, Naether OG, Baukloh V, Tafel J, Nuckel M. Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme. Hum Reprod 1997; 12: 2599-2602.
26. Green-Top guideline No.5: Ovarian Hyperstimulation Syndrome, Management https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg5/. (26 February 2015, date last accessed).
27. Gurbuz AS,GodeF, Ozcimen N, Isik AZ. Gonadotrophin-releasing hormone agonist trigger and freeze-All strategy does not prevent severe ovarian hyperstimulation syndrome: A report of three cases. Reprod Biomed Online 2014; 29: 541-544.
28. Harbin Consensus ConferenceWorkshop Group. Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): Modifying the CONSORT statement. Fertil Steril 2014; 102: 952-959.
29. Hignett M, Spence JE, Claman P. Internal jugular vein thrombosis: A late complication of ovarian hyperstimulation syndrome despite mini-dose heparin prophylaxis. Hum Reprod 1995; 10: 3121-3123.
30. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: Guidance for the clinician. Fertil Steril 2010; 94: 389-400.
31. Knig E, Bussen S, Sutterlin M, Steck T. Prophylactic intravenous hydroxyethyl starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: A prospective, randomized, double-blind and placebo-controlled study. Hum Reprod 1998; 13: 2421-2424.
32. Ling LP, PhoonJW, LauMS,Chan JK,Viardot-FoucaultV,TanTY,Nadarajah S, Tan HH. GnRH agonist trigger and ovarian hyperstimulation syndrome: Relook at 'freeze-All strategy'. Reprod Biomed Online 2014; 29: 392-394.
33. Luke B, Brown MB, Morbeck DE, Hudson SB, Coddington CC, Stern JE. Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome. Fertil Steril 2009; 94: 1399-1404.
34. Maheshwari A, Bhattacharya S. Elective frozen replacement cycles for all: Ready for prime time? Hum Reprod 2013; 28: 6-9.
35. MathurRS,AkandeAV,Keay SD,HuntLP, Jenkins JM.Distinctionbetweenearly and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73: 901-907.
36. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, Porayko M, Moreau R, Garcia-Tsao G et al. The management of ascites in cirrhosis: Report on the consensus conference of the international ascites club. Hepatology 2003; 38: 258-266.
37. Navot D, Relou A, Birkenfield A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988; 159: 210-215.
38. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment. Fertil Steril 1992; 58: 249-261.
39. Neulen J, Yan Z, Raczek S, Weindel K, Keek C, Weich HA, Marme D, Breckwoldt M. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulose cells: Importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995; 80: 1967-1971.
40. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropinreleasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006; 85: 112-120.
41. Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohi J, Simon C. The pathogenesis of ovarian hyperstimulation syndrome: In vivo studies investigating the role of interleukin-1, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999; 71: 482-489.
42. Public Workshop -Risks and Benefits of Hydroxyethyl Starch Solutions. http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/Workshops MeetingsConferences/ucm313370.htm (9 Sepetember 2015, date last accessed).
43. Rabau E, David A, Serr DM, Mashiach S, Lunenfeld B. Human menopausal gonadotropins for anovulation and sterility, results of 7 years of treatment. Am J Obstet Gynecol 1967; 98: 92-98.
44. Rahami M, Leader A, Claman P, Spence J. A novel approach to the treatment of ascites associated with ovarian hyperstimulation syndrome.HumReprod 1997; 12: 2614-2616.
45. Rizk B, Aboulghar MA. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: Brinsden P (ed.) In-Vitro Fertilization and Assisted Reproduction. New York/London: The Parthenon Publishing Group, 1999,131-155.
46. Rollene NL, Amols MH, Hudson SBA, Coddington CC. Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: A case series. Fertil Steril 2009; 92: 1169.e15-e17.
47. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: A current survey. Fertil Steril 1978; 30: 255-268.
48. Tarlatzis BC, Griesinger G, Leader A, Rombauts L, Ijzerman-Boon PC, Mannaerts BM. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. Reprod Biomed Online 2012; 24: 410-419.
49. The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2006; 86(Suppl. 4): S178-S183.
50. Tobler KJ, Zhao Y, Weissman A, Majumdar A, Leong M, Shoham Z. Worldwide survey of IVF practices: Trigger, retrieval and embryo transfer techniques. Arch Gynecol Obstet 2014; 290: 561-568.
51. Tollan A, Holst N, Forsdahl F, Fadnes Ho, Oian P, Maltau JM. Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization. Am J Obstet Gynecol 1990; 162: 554-558.
52. Van Der Linden P, James M, Mythen M, Weiskopf RB. Safety of modern starches used during surgery. Anesth Analg 2013; 116: 35-48.
53. Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: Different products-different effects. Anesthesiology 2009; 111: 187-202.
54. Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, Sullivan E, Vanderpoel S; International Committee for Monitoring Assisted Reproductive Technology; World Health Organization. International Committee for Monitoring Assisted Reproductive Technology (ICMART) and theWorld Health Organization (WHO) revised glossary of ART terminology, 2009. Fertil Steril 2009; 92: 1520-1524.